Factor V Leiden mutation and pregnancy

Journal of the American Board of Family Practice

Volumn 17, Issue 4, 2004, Pages 306-308

  Langan, Robert C ^a,b  

^a St Luke's Family Medicine Residency   (United States)

^b Family Practice Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CLINICAL FEATURE; FEMALE; GENE MUTATION; GENERAL PRACTICE; HUMAN; MEDICAL PRACTICE; NEURAL TUBE DEFECT; PREGNANCY; VAGINAL DELIVERY; VENOUS THROMBOEMBOLISM; GENETICS; POINT MUTATION; PREGNANCY COMPLICATION; RECURRENT ABORTION; VEIN THROMBOSIS;

ABORTION, HABITUAL; ADULT; ANTICOAGULANTS; FACTOR V; FEMALE; HEPARIN; HUMANS; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; VENOUS THROMBOSIS;

EID: 16644393805     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.17.4.306     Document Type: Article

References (17)

1. Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. CMAJ 2002;167:48-54.
2. Macik BG, Rand JH, Konkle BA. Thrombophilia: what's a practitioner to do? Hematology (Am Soc Hematol Educ Program) 2001;322-38.
3. Zoller B, Svensson PJ, He X, Dahlback B. Identication of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
4. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
5. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program) 2002;353-68.
6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
7. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-8.
8. Dizon-Townson D, Nelson LM, Jahn G, Varner MW, Ward K. The incidence of factor V Leiden mutation in an obstetric population and its relationship to deep vein thombosis. Am J Obstet Gynecol 1997;176:883-6.
9. Gerhardt A, Scharf RE, Beckmann MW, et al. Pro-thrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-80.
10. Anticoagulation with low- molecular-weight heparin during pregnancy. ACOG Committee Opinion #221. ACOG 1998. Washington (DC): American College of Obstetricians and Gynecologists; 1998.
11. Cavenaugh JD, Colvin BT. Guidelines for the management of thrombophilia. Postgrad Med J 1996;72:87-94.
12. Hirsch J, Dalen JE, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. Chest 2001;119:122S-131S.
13. Verstraete M, Prentic CRM, Samana M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000;117:1775-70.
14. Barger AP, Hurley R. Evaluation of the hypercoagulable state: whom to screen, how to test and treat. Postgrad Med J 2000;108:59-66.
15. Ghermann RB, Goodwin TM. Obstetrical implications of activated protein C resistance and factor V Leiden mutation. Obstet Gynecol Surv 2000;55:117-22.
16. Younnis JS, Ohel G, Brenner B, et al. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000;107:415-9.
17. Thromboembolism in pregnancy. ACOG Practice Bulletin no. 19. Washington (DC): American College of Obstetricians and Gynecologists; 2000.